

#6

0085599-00101




FIG.1A




FIG. 1B




FIG. 1C




FIG.2A




FIG.2B




FIG.2C




FIG.2D




FIG. 3




FIG. 4





FIG. 6



■ 5.0 µg; x 0.5 µg; △ 0.167 µg; □ 0.05 µg; ◇ 0.017 µg;
 ▲ 50 µg; ◆ 16.7 µg; ◻ 0.005 µg Vij:gD DNA; ○ saline

FIG. 5




FIG. 7

Group ^a	Survivors/ Total (%)	Mean Day to Death	Paralyzed/ Total (%)	Vaginal Virus Titer ^b		
				Day 2 ^c	Day 4	Day 6
Vaccine, 10 µg	8/10 (80)	12.5 ± 0.7	5/10 (50)	3.8 ± 1.9	2.3 ± 1.2	<1.5 ± 0.0
Vaccine, 100 µg	10/10 (100) [†]	>21	0/10 (0)*	3.0 ± 1.3 [∅]	2.0 ± 0.7 [†]	<1.5 ± 0.0
Placebo	6/10 (60)	14.8 ± 4.0	8/10 (80)	5.0 ± 2.3	3.1 ± 1.4	1.6 ± 0.3

^a The vaccine was administered intramuscularly 11 and 4 weeks prior to virus challenge.

^b Log₁₀ cell culture infections doses per ml, determined from vaginal swabs.

^c After virus inoculation.

* P<0.001.

† P=0.08, ∅ P=0.06.

FIG. 8




FIG. 9




FIG.10A




FIG.10B




FIG.11




FIG.12




FIG.13A




FIG.13B




FIG.14A




FIG.14B




FIG.15A




FIG.15B